End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
148.3 USD | 0.00% | 0.00% | -6.76% |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 3.89 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.76% | 350B | - | ||
+39.82% | 734B | C+ | ||
+32.50% | 591B | B | ||
+14.23% | 315B | B- | ||
+0.86% | 276B | C+ | ||
+14.04% | 238B | B+ | ||
-6.54% | 204B | A+ | ||
+8.32% | 206B | B- | ||
+4.51% | 161B | C+ | ||
-2.05% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson